Palvella Therapeutics (PVLA) Research & Development (2014 - 2026)

Palvella Therapeutics (PVLA) has reported Research & Development for 13 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 129.11% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $28.1 million (up 149.99% YoY), while the FY2025 annual figure was $22.8 million, up 180.22% from the prior year.
• Research & Development advanced to $9.3 million in Q1 2026 per PVLA's latest filing, from $7.1 million in the prior quarter.
• Across five years, Research & Development topped out at $14.3 million in Q2 2023 and bottomed at -$28.6 million in Q4 2023.
• Historically, Research & Development has averaged $6.0 million across 5 years, with a median of $7.1 million in 2025.
• Annual changes were most pronounced in 2023 — Research & Development tumbled 313.41% — and 2025, when it jumped 314.02%.
• Palvella Therapeutics' Research & Development stood at $13.4 million in 2022, then sank by 313.41% to -$28.6 million in 2023, then jumped by 108.91% to $2.5 million in 2024, then soared by 180.02% to $7.1 million in 2025, then jumped by 31.08% to $9.3 million in 2026.
• Business Quant data shows PVLA's Research & Development at $9.3 million in Q1 2026, $7.1 million in Q4 2025, and $6.5 million in Q3 2025.